Maisat Wiriya, Yuki Koichi
From the Department of Anesthesiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts.
Anesth Analg. 2025 Aug 5. doi: 10.1213/ANE.0000000000007682.
Perioperative neurocognitive disorders (PND), such as postoperative delirium (POD) and cognitive dysfunction (POCD), frequently affect older surgical patients and significantly impair postoperative quality of life. During surgical procedures, damage-associated molecular patterns (DAMPs) such as high-mobility group box 1 (HMGB1), mitochondrial DNA, and S100 proteins are released from injured cells and implicated in the pathogenesis of PND. These molecules activate innate immune pathways through pattern recognition receptors (PRRs) such as toll-like receptors (TLRs) and receptors for advanced glycation end products (RAGE). The systemic inflammatory response potentially compromises blood-brain barrier integrity, allowing peripheral immune cells to infiltrate the central nervous system. The resulting neuroinflammation disrupts synaptic function and neuronal connectivity, leading to cognitive impairments. Sustained activation of immune pathways creates a feedback loop where proinflammatory cytokines (eg, IL-1β and TNF-α) amplify DAMP release and immune activation, perpetuating chronic inflammation and cognitive dysfunction. Therapeutic strategies targeting DAMP-mediated pathways, such as glycyrrhizin (an HMGB1 inhibitor), dexmedetomidine (an anti-inflammatory anesthetic), and TLR4 inhibitors (eg, TAK-242), have shown promise in reducing neuroinflammation and protecting cognitive function in preclinical models. However, clinical translation requires validated biomarkers and further trials to ensure their safety and efficacy. This review offers a focused perspective on DAMP-specific mechanisms and emerging therapeutic interventions that modulate these pathways. By contributing to the current understanding of DAMPs in the context of PND, this work supports future research efforts aimed at developing biomarkers and targeted interventions to help mitigate postoperative neurocognitive complications in surgical patients.
围手术期神经认知障碍(PND),如术后谵妄(POD)和认知功能障碍(POCD),经常影响老年外科患者,并严重损害术后生活质量。在手术过程中,损伤相关分子模式(DAMP),如高迁移率族蛋白B1(HMGB1)、线粒体DNA和S100蛋白,从受损细胞中释放出来,并与PND的发病机制有关。这些分子通过模式识别受体(PRR)激活先天免疫途径,如Toll样受体(TLR)和晚期糖基化终产物受体(RAGE)。全身炎症反应可能会损害血脑屏障的完整性,使外周免疫细胞浸润中枢神经系统。由此产生的神经炎症会破坏突触功能和神经元连接,导致认知障碍。免疫途径的持续激活会形成一个反馈回路,其中促炎细胞因子(如IL-1β和TNF-α)会放大DAMP的释放和免疫激活,使慢性炎症和认知功能障碍持续存在。针对DAMP介导途径的治疗策略,如甘草酸(一种HMGB1抑制剂)、右美托咪定(一种抗炎麻醉剂)和TLR4抑制剂(如TAK-242),在临床前模型中已显示出减少神经炎症和保护认知功能的前景。然而,临床转化需要经过验证的生物标志物和进一步的试验,以确保其安全性和有效性。本综述聚焦于DAMP特异性机制以及调节这些途径的新兴治疗干预措施。通过促进目前对PND背景下DAMP的理解,这项工作支持了未来旨在开发生物标志物和靶向干预措施的研究努力,以帮助减轻外科患者术后的神经认知并发症。